The FDA’s Office of Prescription Drug Promotion (OPDP) issued its first Warning Letter in nearly two years. While OPDP has sent a dozen Untitled Letters in the last three years, this is the first Warning Letter issued since August 2023. The letter alleges two webpages, a health care provider pamphlet and an exhibit booth panel produced by Sarfez Pharmaceuticals Inc., for Soaa... Read More